Monopar Therapeutics (NASDAQ:MNPR) Trading 10.3% Higher – What’s Next?

Monopar Therapeutics Inc. (NASDAQ:MNPR) shares shot up 10.3% on Tuesday . The company traded as high as $75.80 and last traded at $75.75. 57,507 shares traded hands during mid-day trading, a decline of 72% from the average session volume of 206,877 shares. The stock had previously closed at $68.66.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on the stock. HC Wainwright reissued a “buy” rating on shares of Monopar Therapeutics in a research report on Tuesday, June 2nd. Chardan Capital reaffirmed a “buy” rating and issued a $100.00 price target on shares of Monopar Therapeutics in a report on Monday, March 30th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Monopar Therapeutics in a research note on Tuesday, April 21st. Wall Street Zen lowered Monopar Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, June 14th. Finally, Piper Sandler set a $105.00 target price on Monopar Therapeutics in a research report on Tuesday, June 2nd. Two research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Monopar Therapeutics currently has a consensus rating of “Buy” and an average price target of $107.91.

Monopar Therapeutics Trading Up 8.8%

The firm has a market cap of $596.23 million, a P/E ratio of -46.84 and a beta of 1.52. The business’s fifty day simple moving average is $61.07 and its 200-day simple moving average is $61.90.

Monopar Therapeutics (NASDAQ:MNPR) last posted its quarterly earnings results on Thursday, May 14th. The company reported ($0.46) EPS for the quarter, topping analysts’ consensus estimates of ($0.87) by $0.41. As a group, research analysts expect that Monopar Therapeutics Inc. will post -2.82 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in MNPR. Goldman Sachs Group Inc. bought a new stake in shares of Monopar Therapeutics during the first quarter valued at about $673,000. Jane Street Group LLC bought a new position in shares of Monopar Therapeutics in the first quarter valued at approximately $377,000. Geode Capital Management LLC grew its stake in Monopar Therapeutics by 99.7% during the second quarter. Geode Capital Management LLC now owns 96,919 shares of the company’s stock valued at $3,468,000 after acquiring an additional 48,379 shares in the last quarter. JPMorgan Chase & Co. increased its holdings in Monopar Therapeutics by 1,821.0% during the 2nd quarter. JPMorgan Chase & Co. now owns 1,921 shares of the company’s stock worth $69,000 after acquiring an additional 1,821 shares during the period. Finally, Rhumbline Advisers bought a new stake in Monopar Therapeutics during the 2nd quarter worth approximately $209,000. Hedge funds and other institutional investors own 1.83% of the company’s stock.

Monopar Therapeutics Company Profile

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.